COPD Special Report: The Year in Review

Telemedicine follow-up after hospital discharge for COPD exacerbation was significantly more effective than standard care and received high patient satisfaction scores.

Astegolimab did result in a statistically significant reduction of annualized exacerbation rates in a similar phase 2b trial, but the result was not replicated in phase 3.

Verekitug is the only biologic in development for COPD that targets the TSLP receptor directly.

Itepekimab performed well in the phase 3 AERIFY-1 trial but fell short of anticipated outcomes in AERIFY-2, prompting further analysis after the mixed results.

Dupilumab significantly reduced COPD exacerbations and received high satisfaction ratings from patients with severe disease and Th2 inflammation.

Mepolizumab, an IL-5 inhibitor targeting Th2 inflammation characterized by elevate serum eosinophil count, fills a treatment gap for ~70% of adults with uncontrolled COPD.